A118000 Stock Overview
Wooridul Huebrain Limited engages in the medical, life and health, pharmaceutical, and storage businesses.
Wooridul Huebrain Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||₩1,155.00|
|52 Week High||₩2,325.00|
|52 Week Low||₩1,065.00|
|1 Month Change||-12.50%|
|3 Month Change||-13.81%|
|1 Year Change||-40.31%|
|3 Year Change||-49.56%|
|5 Year Change||-63.39%|
|Change since IPO||-87.71%|
Recent News & Updates
There Are Some Holes In Wooridul Huebrain's (KRX:118000) Solid Earnings Release
Following the release of a positive earnings report recently, Wooridul Huebrain Limited's ( KRX:118000 ) stock...
|A118000||KR Healthcare||KR Market|
Return vs Industry: A118000 matched the KR Healthcare industry which returned -39.9% over the past year.
Return vs Market: A118000 underperformed the KR Market which returned -14.2% over the past year.
|A118000 Average Weekly Movement||4.5%|
|Healthcare Industry Average Movement||5.8%|
|Market Average Movement||5.5%|
|10% most volatile stocks in KR Market||10.4%|
|10% least volatile stocks in KR Market||3.2%|
Stable Share Price: A118000 is not significantly more volatile than the rest of KR stocks over the past 3 months, typically moving +/- 4% a week.
Volatility Over Time: A118000's weekly volatility (4%) has been stable over the past year.
About the Company
Wooridul Huebrain Limited engages in the medical, life and health, pharmaceutical, and storage businesses. It sells medical equipment and appliances, health equipment, medicines, and computer servers. Wooridul Huebrain Limited was formerly known as Wooridul Life Sciences Limited and changed its name to Wooridul Huebrain Limited in April 2014.
Wooridul Huebrain Fundamentals Summary
|A118000 fundamental statistics|
Is A118000 overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|A118000 income statement (TTM)|
|Cost of Revenue||₩13.55b|
Last Reported Earnings
Dec 31, 2021
Next Earnings Date
|Earnings per share (EPS)||115.89|
|Net Profit Margin||52.74%|
How did A118000 perform over the long term?See historical performance and comparison
Is Wooridul Huebrain undervalued compared to its fair value and its price relative to the market?
Valuation Score 3/6
Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PB vs Industry
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate A118000's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate A118000's fair value for valuation analysis.
Price To Earnings Ratio
PE vs Industry: A118000 is good value based on its PE Ratio (10x) compared to the Asian Healthcare industry average (17.4x).
PE vs Market: A118000 is good value based on its PE Ratio (10x) compared to the KR market (14x).
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate A118000's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: A118000 is good value based on its PB Ratio (0.8x) compared to the KR Healthcare industry average (2.3x).
How is Wooridul Huebrain forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Future Growth Score0/6
Future Growth Score 0/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted Healthcare industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Wooridul Huebrain has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has Wooridul Huebrain performed over the past 5 years?
Past Performance Score1/6
Past Performance Score 1/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: A118000 has a large one-off gain of ₩10.1B impacting its December 31 2021 financial results.
Growing Profit Margin: A118000's current net profit margins (52.7%) are lower than last year .
Past Earnings Growth Analysis
Earnings Trend: A118000 has become profitable over the past 5 years, growing earnings by 56.5% per year.
Accelerating Growth: A118000's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: A118000 had negative earnings growth (-21%) over the past year, making it difficult to compare to the Healthcare industry average (33.2%).
Return on Equity
High ROE: A118000's Return on Equity (8.3%) is considered low.
How is Wooridul Huebrain's financial position?
Financial Health Score4/6
Financial Health Score 4/6
Short Term Liabilities
Long Term Liabilities
Financial Position Analysis
Short Term Liabilities: A118000's short term assets (₩80.4B) exceed its short term liabilities (₩53.3B).
Long Term Liabilities: A118000's short term assets (₩80.4B) exceed its long term liabilities (₩3.6B).
Debt to Equity History and Analysis
Debt Level: A118000 has more cash than its total debt.
Reducing Debt: A118000's debt to equity ratio has reduced from 64.8% to 24.8% over the past 5 years.
Debt Coverage: A118000's operating cash flow is negative, therefore debt is not well covered.
Interest Coverage: Insufficient data to determine if A118000's interest payments on its debt are well covered by EBIT.
What is Wooridul Huebrain current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate A118000's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate A118000's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if A118000's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if A118000's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as A118000 has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Soo-Kyung Kim (72 yo)
Ms. Soo-Kyung Kim served as Chief Executive officer of Wooridul Pharmaceutical Limited (formerly known as Wooridul Life Sciences Ltd). Ms. Soo-Kyung Kim served as Co-Chief Executive Officer of Sudo Pharmac...
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 68.1%.
Wooridul Huebrain Limited's employee growth, exchange listings and data sources
- Name: Wooridul Huebrain Limited
- Ticker: A118000
- Exchange: KOSE
- Founded: 2009
- Industry: Health Care Distributors
- Sector: Healthcare
- Implied Market Cap: ₩97.832b
- Shares outstanding: 84.70m
- Website: https://www.wooridulls.co.kr
Number of Employees
- Wooridul Huebrain Limited
- 156, No. 202, Dream Building)
- South Korea
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/05/23 00:00|
|End of Day Share Price||2022/05/23 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.